Weekly Signals Desk | Concentrated Analyst Revisions via the FMP API (Sept 7-11)

Four downgrades landed on Cooper Companies inside a single session, and every one of them cited the same two facts: a soft quarter in contact lenses and a business the company had decided, after months of review, not to sell. That is what a genuine cluster looks like. The rest of the week's screen was more varied, with Synopsys drawing two upgrades, Amgen and Chewy each collecting two downgrades, and Novartis pulling an upgrade and a downgrade within days of one another.

Using FMP's Stock News API alongside the Stock Grades API, this article works through what each cluster actually repriced, why several of these revisions had little to do with the reported quarter, and how clustered ratings activity can be converted into a repeatable research input rather than a headline feed.

Key Takeaways

• Cooper Companies absorbed four downgrades in one day, but the common thread across the notes was the abandoned divestiture rather than the earnings miss, which removed a valuation argument several desks had been relying on.
• Two of the five clusters were triggered by events outside the company's own reporting. Amgen was downgraded into a rally, and the sharpest news of its week concerned a competitor's failed trial.
• Synopsys shows how to read a rating round trip: both upgrading firms had previously stepped aside on the same integration question, and returned once that question resolved.
• Split coverage, as at Novartis, carries different information than a one-sided cluster. When two firms move in opposite directions in the same week, the disagreement is usually about time horizon rather than facts.

Five Names Where the Sell Side Rewrote Its Assumptions

Cooper Companies (COO) - 4 Downgrades

William Blair, BofA Securities, Baird and Piper Sandler all cut Cooper Companies within the same window, with BofA moving to Neutral and lowering its objective to $65 from $80, Baird to Neutral at $61 from $85, and Piper Sandler to Neutral at $59 from $86. The fiscal third quarter itself was not dramatic: revenue came in near $1.07 billion with roughly 1% organic growth, CooperVision flat, CooperSurgical up around 3% organic on fertility strength, and free cash flow up sharply. Full-year guidance was trimmed.

What made this a four-firm cluster was the second announcement. Cooper concluded its strategic review of CooperSurgical and decided to retain the business. Several of the notes had been built, explicitly or otherwise, on a sum-of-the-parts argument in which a sale would surface value the market was not crediting. BofA framed the absence of an acceptable buyer as evidence that the asset carries a structurally lower valuation, and once that is accepted, the optionality leaves the model for an extended period. Baird and Piper Sandler both pointed to a pattern of guidance reductions rather than a single disappointment, with Piper noting a fourth cut to the CooperVision outlook in roughly two years.

The analytical point is that the downgrades are about repeatability, not magnitude. Multiple desks now describe the forecasting problem at CooperVision as widening rather than narrowing, which is a harder thing to fix than a weak quarter. Several notes observed that the shares would be trading at a multi-year trough multiple, and none treated that as sufficient reason to stay constructive. FMP's Financial Estimates API is the right place to test whether the reset has actually reached forward revenue and EPS consensus or has so far only moved ratings, since a cluster that changes recommendations without changing numbers tends to be less durable than one that does both.

Synopsys (SNPS) - 2 Upgrades

Morgan Stanley moved Synopsys to Overweight with a $500 objective, and Wells Fargo also moved to Overweight, raising its target to $475 from $450. Morgan Stanley's note is unusually explicit about why the rating had been lower in the first place: it had stepped aside earlier in the year pending visibility on profitability from the Ansys integration, a return to teens-percentage growth in EDA, and evidence that the co-design offering carried real strategic weight. Two of those three conditions now look satisfied enough to change the rating.

The reported quarter supports the shift in a specific way. Revenue rose sharply year over year with Design Automation carrying most of the growth at a mid-forties operating margin, and Design IP returned to year-over-year growth after a period of contraction. That IP inflection is the detail that matters most, because the Design IP slowdown was the concrete evidence behind the earlier caution. Morgan Stanley's forward argument leans on the transition toward physical AI, where simulation of thermal, mechanical and fluid behaviour becomes part of the design loop, which is precisely the capability the Ansys acquisition added.

Reading this as a round trip rather than a fresh call changes what to watch. An upgrade that reverses a prior downgrade from the same firm is a statement that a specific diagnostic condition was met, which makes the condition itself the thing to track. FMP's Historical Stock Grades API reconstructs that sequence for a given name, and seeing when a firm stepped aside and on what basis is often more informative than the current rating. The upcoming investor day is where management has the opportunity to put figures against the IP recovery and the integration synergies that both notes are now underwriting.

Amgen (AMGN) - 2 Downgrades

HSBC moved Amgen to Hold with a $425 target, and BMO Capital to Market Perform at $450. Neither downgrade describes a deteriorating business. HSBC states plainly that its long-term thesis is unchanged and that the company can work through its patent cliff, while BMO opens by noting that commercial execution is now the base case with the shares up substantially year to date against a far more modest move in the broader market. These are valuation and expectation calls, and they are the cleanest example in this week's screen of a downgrade arriving because a stock worked.

The more interesting element is the timing. In the same window, a competing Lp(a)-lowering therapy from another large-cap developer failed to meet its primary cardiovascular outcomes endpoint in a Phase III trial of more than 8,000 patients, showing that lowering the biomarker did not translate into fewer cardiovascular events. Amgen's olpasiran targets the same biology through a different mechanism and remains in its own outcomes study. HSBC flags that read-through directly as part of the rationale for a more balanced risk profile. A downgrade grounded partly in another company's data is a useful reminder that revision clusters do not always map to the company's own disclosure calendar.

Both firms also point to the same structural issue: the visible pipeline value drivers sit in 2027 and beyond, while steady patent expiries cap near-term growth. That combination, an expensive present and a back-ended catalyst set, is what leaves the risk-reward described as balanced rather than attractive. FMP's Price Target Summary API is the appropriate lens here because it exposes the dispersion and recency of targets across the coverage group, and dispersion is the measure that tends to widen when the sell side is split on a binary clinical outcome rather than on operating performance.

Chewy Inc. (CHWY) - 2 Downgrades

JPMorgan moved Chewy to Neutral with a $24 target from $29, and Evercore ISI to In Line at $25. The quarter was not weak in the conventional sense. Net sales grew roughly 7% to $3.33 billion, autoship reached close to 85% of the mix, adjusted EBITDA margin of 6.8% cleared the top of management's guidance range, and the full-year sales outlook was raised modestly. Both firms nevertheless concluded that the setup no longer supports an above-market rating.

The reasoning is almost entirely about growth composition. Evercore points to organic growth decelerating to the high-single digits and describes the category as reasonably mature with rising competitive intensity, arguing that this trajectory removes the conditions for a valuation re-rating. JPMorgan is more granular and, in places, more constructive: it notes continued share gains at roughly two to three times the broader pet category, healthy customer additions, and acquisitions performing ahead of plan. It also identifies the margin qualifier that matters most, namely that most of the EBITDA upside came from timing-related items including tariff refunds, rebates and breakage rather than from underlying operating leverage, with gross margin expected to step down sequentially and marketing spend weighted toward the second half.

That distinction is the whole signal. A quarter where reported margin beats guidance but the beat is discrete is a different input than one where cost structure is genuinely improving, and both desks have effectively marked the difference. Sponsored advertising, fulfilment efficiency and lower variable cost to serve are described as real contributors, which means the question is one of pace rather than direction. FMP's Cash Flow Statement API is the most direct way to test that over several quarters, since working-capital movement and cash conversion will show whether margin gains are being retained once the one-off items wash out.

Novartis (NVS) - 1 Upgrade, 1 Downgrade

Novartis is the only split in the screen. HSBC lifted the shares from Reduce to Hold with a $136 target, while Deutsche Bank moved from Buy to Hold with a CHF 120 objective. Both firms landed on the same rating from opposite directions inside the same week, which is a configuration worth pausing on. It is not disagreement about the business. It is two models converging on a neutral stance after starting from very different assumptions about how much the market had already priced.

Context makes the convergence legible. The company is working through what management has described as the largest patent expiry period in its history, with the growth case resting on pipeline readouts rather than on the existing portfolio. Then, within the same window, its Phase III cardiovascular outcomes trial for pelacarsen missed its primary endpoint across a large patient population. Removing a late-stage asset from a growth bridge that was already carrying a heavy loss-of-exclusivity load is the kind of event that pulls an optimistic model down and, for a firm that had been negative on valuation grounds, brings the share price closer to where its more cautious assumptions already sat.

The practical read is that split coverage marks a genuine reset in the range of outcomes rather than a directional view. For a company in a patent-cliff transition, the useful monitoring is the distribution of ratings across the full coverage group rather than any single action, and FMP's Ratings Snapshot API provides that aggregate position. Watching how that distribution tightens or disperses around the remaining pipeline readouts is more informative than either of this week's individual moves.

Reading the Clusters: What Was Actually Repriced

The instinct with revision data is to count. Four downgrades outrank two, and a split cancels out. This week makes the case for reading the content instead, because the five clusters were triggered by five different classes of information and only one of them was a conventional reaction to reported results.

Cooper was repriced on a structural decision, not a quarter: an abandoned divestiture removed a valuation argument, and the earnings miss simply supplied the occasion. Synopsys was repriced on the resolution of a diagnostic condition that the upgrading firms had stated in advance. Amgen was repriced on its own share performance and on a competitor's trial failure, a combination in which the company itself disclosed nothing. Chewy was repriced on the quality of a margin beat rather than its size. Novartis was repriced by two firms travelling in opposite directions toward the same neutral conclusion. Rank those by revision count and the ordering tells you almost nothing useful. Sort them by what changed in the model and a pattern appears: in four of five cases, the sell side adjusted the durability of an assumption rather than the level of a forecast.

That distinction is where combining datasets earns its keep, and it is the reason the broader endpoint coverage available through FMP is more useful than any single ratings feed. The Historical Ratings API establishes whether a firm is reversing itself or extending a view, which separates a round trip like Synopsys from a first-time reassessment. The Price Target Consensus API then measures the size and dispersion of the valuation reset, and dispersion is what distinguishes a coverage group with a shared model from one split on a binary outcome. Where those two disagree, with ratings moving but targets clustered tightly, the cluster is usually a sentiment event rather than an analytical one.

The next test is whether the revisions have reached the numbers. Comparing rating changes against the Financial Estimates API shows whether forward revenue, EBITDA and EPS lines moved alongside the recommendations, and a cluster that leaves consensus estimates intact has a shorter shelf life than one that drags them down with it. Where the question is whether reported performance supports the revised view, the Income Statement API and Key Metrics TTM API provide the reconciliation, with the latter normalizing free cash flow yield and return measures across businesses as different as a contact lens manufacturer, an EDA platform and an online retailer. Cooper's guidance record, Chewy's cash conversion and Amgen's expiry schedule are not comparable in raw form, and they become so only once trailing metrics put them on the same footing. A revision cluster identifies where consensus is in motion. The financial data determines whether that motion has anything behind it.

Turning Analyst Revisions Into a Structured Research Workflow

Analyst ratings only become actionable when you stop treating them as isolated headlines and start handling them as structured data. The goal is straightforward: capture changes as they happen, standardize them, and then connect those changes back to real-world events. Before anything else, make sure your API key is active and ready to run.

1. Pull Latest Analyst Ratings

Begin with a fresh pull from the Stock News API. This endpoint aggregates recent market-moving headlines, including upgrades and downgrades. It's the fastest way to establish a baseline of who changed their view and when, without needing to scrape multiple sources.

Endpoint:

https://financialmodelingprep.com/stable/news/stock-latest?page=0&limit=20&apikey=YOUR_API_KEY

Sample Response:

[ { "symbol": "INSG", "publishedDate": "2025-02-03 23:53:40", "publisher": "Seeking Alpha", "title": "Q4 Earnings Release Looms For Inseego, But Don't Expect Miracles", "image": "...", "site": "seekingalpha.com", "text": "Inseego's Q3 beat was largely due to a one-time debt restructuring gain, not sustainable earnings growth, raising concerns about future performance. The sale of its telematics business for $52 million allows INSG to focus on North America, but it remains to be seen if this was wise. Despite improved margins and reduced debt, Inseego's revenue growth is insufficient, and its high stock price remains unjustifiable for new investors.", "url": "https://seekingalpha.com/article/4754485-inseego-stock-q4-earnings-preview-monitor-growth-margins-closely" } ]

2. Isolate Rating Changes

From that initial feed, filter for entries that explicitly reference upgrades or downgrades. This step is about narrowing the universe—identifying which tickers are actually seeing analyst activity versus general news flow. Once you have that subset, you're ready to move from raw headlines to structured tracking.

3. Quantify the Activity

For each ticker identified, call the Stock Grades API to retrieve the latest analyst actions tied specifically to that name. This is where the workflow shifts from collection to measurement.

Group the results by ticker and separate upgrades from downgrades. Single mentions tend to be incidental; repeated actions across multiple firms indicate something more deliberate. This aggregation step is what surfaces clusters—names where sentiment is actively being recalibrated.

4. Map the Catalyst

Once the high-activity names are clear, the next step is attribution. Use the Search Stock News API to pull company-specific headlines and align rating changes with underlying developments—earnings releases, M&A announcements, regulatory updates, or sector-wide shifts.

Endpoint:

https://financialmodelingprep.com/stable/news/stock?symbols=AAPL&apikey=YOUR_API_KEY

Example Workflow: Finding the “Most Active” Stocks

1. Pull a rolling seven-day window of headlines from the Stock News API and filter for upgrades/downgrades.
2. Extract tickers that appear at least once with a rating change.
3. For each ticker, query the Stock Grades API to retrieve the full set of recent analyst actions.
4. Count total upgrades and downgrades per name.
5. Prioritize tickers with three or more revisions (or another threshold aligned with your coverage).
6. Run those tickers through the Search Stock News API to line up rating shifts with the underlying catalyst.

Scaling Analyst Workflows Across the Organization

Workflows built around analyst revisions rarely remain isolated for long once they begin producing repeatable signal quality. Inside most firms, the transition usually starts when a handful of analysts consistently surface actionable sentiment shifts earlier than the broader desk — not because they have access to different information, but because their process for structuring and contextualizing that information is more systematic. Over time, those workflows tend to move from individual notebooks and spreadsheets into shared operating infrastructure.

That evolution changes the role of the data itself. Analyst revisions stop functioning as scattered research notes and become part of a governed internal framework that can be referenced across research, portfolio management, and risk teams simultaneously. Centralized dashboards replace duplicated manual tracking, standardized query logic reduces interpretation drift between teams, and structured datasets create an audit trail around how sentiment changes were identified and interpreted. The operational benefit is not simply speed — it is consistency. When multiple desks are evaluating the same revision clusters against the same underlying financial and market data, internal discussions become materially less fragmented.

In practice, analysts often become the internal champions driving that standardization effort. After pressure-testing workflows across multiple earnings cycles, they begin codifying the inputs that proved most reliable: revision velocity, estimate changes, target dispersion, earnings transcript language, sector-relative performance, and catalyst alignment. Once standardized, those inputs become reusable across broader coverage universes rather than dependent on individual institutional knowledge. That continuity becomes increasingly important as coverage rotates, teams expand, or macro conditions force firms to reevaluate exposure across sectors quickly.

Infrastructure becomes increasingly relevant at that stage because scaling a workflow across teams requires more than simply increasing API usage. The underlying data pipelines, timestamps, outputs, and revision histories need to remain consistent and traceable across users and mandates. The Financial Modeling Prep Enterprise plan tend to fit into this layer less as standalone data products and more as centralized coordination systems — enabling firms to maintain shared reference frameworks as analyst sentiment, earnings revisions, and positioning data evolve over time.

Where the Rewrite Happens Before the Numbers Do

The most useful clusters this week were the ones that had little to do with the quarter just reported: a divestiture that did not happen, a competitor's trial that did not work, a margin beat that will not repeat. Tracking those moments through FMP's Stock News API and Stock Grades API is how a desk sees an assumption being rewritten while the reported financials still look the same.

For additional trading ideas backed by data, explore: Weekly Signals Desk | Price-Target Gaps Identified via the FMP API (Aug 31-Sept 4)

Disclosure: Signals Desk content is provided for informational and analytical purposes only and does not constitute investment advice or trade recommendations. The analysis reflects interpretation of market data and publicly disclosed or third-party information, including data accessed via Financial Modeling Prep APIs, at the time of publication. Signals discussed are probabilistic, can be wrong, and may change as market conditions and consensus data evolve. This content should be considered alongside broader research, individual objectives, and risk assessment.